An SMD 0.5 large imbalance
Additionally, semaglutide 2.4mg sc has shown a reduction in cardiovascular mortality, non-fatal myocardial infarction or stroke, and symptoms of heart failure, while tirzepatide has demonstrated a reduction in cardiovascular mortality and heart failure symptoms in patients with obesity and heart failure
104 Similarly, Bolam et al.s 9-month combined exercise intervention (upper-body resistance + varying doses of impact loading) in middle-aged and elderly obese men revealed minimal changes ( 1%) in whole-body, lumbar spine and femoral neck BMD, with no between-group differences in bone turnover markers (BAP and CTX-1)
Direct Food Associations PFAS arises due to cross-reactivity
GLP-1 Kidney Cancer Risks In this latest study, researchers from the Regenstrief Institute in Indianapolis and the University of Florida conducted a retrospective study looking at clinical trials from 2014 to 2024 involving a total of 86,632 matched adults